

WC200103312 (1) PCT/GB01/000001

12 AAM38761 standard; protein; 702 AA.  
22  
A AAM38761;  
22  
PT A2-GCT 2001 (first entry)  
22  
DE Human polypeptide SEQ ID NO: 2006.  
22  
FW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
FW peripheral nervous system; neuropathy; central nervous system; CNS;  
FW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
FW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
FW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
FW leukaemia.  
22  
QS Homo sapiens.  
22  
PN WO2001051811-A1.  
22  
PD 26-JUL-2001.  
22  
PF 26-DEC-2000; 2000WO-US24263.  
22  
PF 21-JAN-2000; 2000US-0488725.  
PF 25-APR-2000; 2000US-0552317.  
PF 09-JUL-2000; 2000US-0598042.  
PF 19-JUL-2000; 2000US-0610312.  
PF 03-AUG-2000; 2000US-0613450.  
PF 14-SEP-2000; 2000US-0662191.  
PF 19-OCT-2000; 2000US-0663035.  
PF 23-NOV-2000; 2000US-0727344.  
22  
PA HYSE-1 HI/SEQ INC.  
22  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Shao ZA, Shao P, Goodrich R, Drmanac RT;  
22  
WPI; 2001-442253/47.  
22  
N-PDB; AAI58937.  
22  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries -  
22  
PS Example 4; SEQ ID NO: 924; 10078pp; English.  
22  
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC central nervous system diseases, such as  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilization of the activities such as: Immune system suppression,  
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC and assays for receptor activity, arthritis and inflammation, leukaemias and  
CC C.N.S disorders.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification.  
XX  
SQ Sequence 772 AA;

Query Match 100.0 ; Score 4037; DB 22; Length 772;  
 Best Local Similarity 100.0 ; Pred. No. 0;  
 Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MRLSSILALLRPALPLILGLSLGISLSLLRVSWIPEGEGEDPCVEAVGERGGPQNPDSEAR 60  
 ||||||| 1 mrlssllailrpalplilglsglsisllrvsui pgegedpcveavgerggpqpdsrar 60

Dk 1 LDQ5DEDIFKPRIVPPYRDPNPKPYKKVLFTRYIQTTELGSRERLLVAVLTSRATLSTLAVAV 120  
 ||||||| 1 ldq5dedifkpri ppyrddpnkpykkvltryi qtelgsrerllvavlttsratlstlavav 120

Qy 1 NPTVAHHFPRLLYFTGQFGARAFAGMQVVSHGDEFFAWLMSETLRHLHTHFGADYDWFFI 180  
 ||||||| 1 nrtvahhfprllytgqgarapagmqrushqderpawimsetlrhlhthfgadydwffi 180

Dk 1 MQDDTYVQAPPLAALAGHLSINQDLYLGRAEEFIGAGEQARYCHGGFGYILSFSLLLFLF 240  
 ||||||| 1 mqddtyvqaprlaalaghlsinqdlyg:aeef:qageqarychggfgyllarsllrlr 240

Qy 1 PHLDCRGDILSAPPDEWLGFCLIDSLGVGCNSQHQGQ2YRSFELAKNRDPKEGSSAFL 300  
 ||||||| 1 phldicrgdilisappdewlgcrlidslgvcus qqqqyrsfelaknrdpekegssafi 300

Dk 1 SAFAVHPVSEGTLMYRLHKRFSALELERAYSHIEPLQADQIRNLTVLTPGEAGLSWF/GL 360  
 ||||||| 1 safavhpvsegltmyrlhkrfsalelerayseieplqajirnltvltpgeaja, lswpvg 360

Qy 1 PAPFTPHSRFE/LGWDYFTEQHTFSCALGAPKCPDQGASRADVGDALETALEPLNRYQP 420  
 ||||||| 1 papftphsrfevlgwdfyteqhtfscadgapkcpdqgasradvgdaletaleplnrryqp 420

Dk 1 RLRFQKQRLLLNGYRRFDPARGMEYTLDLLECVTQFGHRRALARRVSSLRELSEVILPM 480  
 ||||||| 1 rlrfqkqrllyngyrrfdpargmeytld.llecvtqrgrralarrvsslrlplsrvilpm 480

Qy 1 PYTEATRQVQVLPILLVAEAAAAPAFLEAFAAVIEPREHALLTLLVIGPREGGRGAPD 540  
 ||||||| 1 pyteatrvqvlpillvaеaaaапafleafaa:ieprehalltlllywgpreggrgapd 540

Dk 1 PFLGVKAААЕЛЕАРЫГТFLAWLAVPAAEASW/RLMDV/SKKHFVDTLFFLTTWTRPG 600  
 ||||||| 1 pflgvkaaaеелerrygtrlawlavraeaps purimdvvskhfpvdtlfllttwtrpg 600

Qy 1 PEVLNRCRMMAISGWQAFFPVHFEQEFNPALSPQRSPGEPGAGFDPFSPPGADESKGAPI 660  
 ||||||| 1 pevlnrcrmmaisgwqaaffpvhfgefnpalspqrspgppgagpdpssppgadpsrgapi 660

Dk 1 PEVLNRCRMMAISGWQAFFPVHFEQEFNPALSPQRSPGEPGAGFDPFSPPGADESKGAPI 660  
 ||||||| 1 pevlnrcrmmaisgwqaaffpvhfgefnpalspqrspgppgagpdpssppgadpsrgapi 660

27 461 GGFYRQASAEQDFYNALYLNAPARLAGLFLAGQEEEEALEGLEMIVFLPFQGLMLFRWV

721 EPGLVCKFSLRDCSEPLSEEIYHRCPLSNLEGLGGRAQLAMALFEGEQANIST 772

DB 724 epqlvqkfsirdcspri see lhrkrishnqibbrai anateqam

## RESULT 2

AE30263

ID AAB80269 standard; Protein: 772 AA.

222

A: AHB60263;

222

LT 24-APR-2001 (first entry)

۲۰۴

PE Human PEO33 $\beta$  protein.  
XX Human; FFD; dermatological; antipsoriatic; cytostatic; antiinflammatory;  
FW antiparkinsonian; neurotropic; neuroprotective; vulnerary; cardiant;  
FW antiangogenic; vasoactive; antiasthmatic; antirheumatic; cancer;  
FW antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;  
FW ophthalmological; gene therapy; skin disease; gastrointestinal disorder;  
FW ischaemia; inflammation.

10

### 2.3 *Homo sapiens*.

117

EN WC200104311-A1.

11

PD 18-JAN-2001.

5

PL 112-FEB-2000; 2000WC-US04414.

11

PF	07-JUL-1999;	99WJ-0143048.
PF	16-JUL-1999;	99WJ-0145698.
PF	18-JUL-1999;	99WJ-0146222.
FF	08-SEP-1999;	99WI-US20594.
PF	13-SEP-1999;	99WI-US20944.
FF	15-SEP-1999;	99WI-US21090.
FF	15-SEP-1999;	99WI-US21547.
FF	05-OCT-1999;	99WI-US23089.
FF	29-NOV-1999;	99WI-US28214.
FF	30-NOV-1999;	99WI-US31813.
FF	16-DEC-1999;	99WI-US30095.
FF	20-DEC-1999;	99WI-US30911.
FF	20-DEC-1999;	99WI-US31993.
PF	05-JAN-2000;	99WI-US01219.

2

RECEIVED : GENENTECH INC.

PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N,  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;  
PI Mather CB, Pan J, Pachl NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;

ID AAI57798-1140; cDNA: 2710 BP.  
AC AAI57798;  
DT 21-OUT-2001 first entry  
DE Human polynucleotide SEQ ID NO 1140.  
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;  
KW peripheral nervous system; neuropathy; central nervous system; CNS;  
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;  
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;  
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;  
KW leukaemia; cs.  
OS Homo sapiens.  
XX  
PN WO200153312 A1.  
XX  
PD 26-JUL-2001  
XX  
PP 26-DHC-2000; 2000WO-US34263.  
XX  
PR 21-JAN-2000; 2000US-0488725.  
PR 25-APR-2000; 2000US-0552317.  
PR 09-JUL-2000; 2000US-0598042.  
PR 19-JUL-2000; 2000US-0620312.  
PR 03-AUG-2000; 2000US-0653450.  
PR 14-SEP-2000; 2000US-0662191.  
PR 19-OCT-2000; 2000US-0693036.  
PR 29-NOV-2000; 2000US-0727344  
XX  
PA (HYSEQ-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;  
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;  
PI Zhao QA, Shou P, Goodrich R, Drmanac RT;  
XX  
DR WPI: 2001-442253/47.  
DR P-PSDB; AAM39781.  
XX  
PT Novel nucleic acids and polypeptides, useful for treating disorders  
PT such as central nervous system injuries.  
XX  
PS Claim 1; SEQ ID NO 1140, 10078pp; English.  
XX  
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and  
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,  
CC immunosuppressant and cytostatic activity. The polynucleotides are useful  
CC in gene therapy. A composition containing a polypeptide or polynucleotide  
CC of the invention may be used to treat diseases of the peripheral nervous  
CC system, such as peripheral nervous injuries, peripheral neuropathy and  
CC localised neuropathies and central nervous system diseases, such as  
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the  
CC utilisation of the activities such as: immune system suppression,  
CC Activin/inhibit activity, chemotactic/chemokinetic activity, haemostatic  
CC anti-thrombolytic activity, cancer diagnosis and therapy, drug screening,  
CC and assays for receptor activity, arthritis and inflammation, leukaemias and  
CC CNS disorders.  
CC Note The sequence data for this patent did not form part of the printed  
CC specification.  
XX  
UQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;  
UQ

Query Match 96.5%; Score 2692; DB 22; Length 2710;  
Best Local Similarity 100.0%; Pred. No. 0;  
Matches 2692; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DY 96 ggggttagttccgacacottcacagttgaagagcagggagaaggatgtgaagacagg 157





